A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Moderna, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 2,772 shares of MRNA stock, worth $102,148. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,772
Previous 733 278.17%
Holding current value
$102,148
Previous $87,000 112.64%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$63.64 - $125.14 $129,761 - $255,160
2,039 Added 278.17%
2,772 $185,000
Q4 2023

Jan 31, 2024

SELL
$69.51 - $104.43 $268,795 - $403,830
-3,867 Reduced 84.07%
733 $72,000
Q2 2023

Jul 06, 2023

SELL
$118.5 - $160.53 $47,400 - $64,212
-400 Reduced 8.0%
4,600 $558,000
Q3 2022

Nov 14, 2022

SELL
$118.07 - $194.18 $283,368 - $466,032
-2,400 Reduced 32.43%
5,000 $591,000
Q2 2022

Aug 16, 2022

SELL
$117.13 - $176.59 $93,704 - $141,272
-800 Reduced 9.76%
7,400 $1.06 Million
Q4 2021

Feb 14, 2022

SELL
$225.82 - $368.51 $293,566 - $479,063
-1,300 Reduced 13.68%
8,200 $2.08 Million
Q3 2021

Oct 28, 2021

SELL
$221.9 - $484.47 $177,520 - $387,576
-800 Reduced 7.77%
9,500 $3.66 Million
Q2 2021

Jul 13, 2021

BUY
$129.91 - $234.98 $467,676 - $845,928
3,600 Added 53.73%
10,300 $2.42 Million
Q1 2021

May 07, 2021

BUY
$109.18 - $185.98 $272,950 - $464,950
2,500 Added 59.52%
6,700 $877,000
Q4 2020

Mar 02, 2021

BUY
$65.74 - $169.86 $138,054 - $356,706
2,100 Added 100.0%
4,200 $439,000
Q3 2020

Nov 09, 2020

SELL
$54.34 - $94.85 $103,246 - $180,215
-1,900 Reduced 47.5%
2,100 $149,000
Q2 2020

Jul 08, 2020

BUY
$29.67 - $80.0 $118,680 - $320,000
4,000 New
4,000 $257,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Livforsakringsbolaget Skandia, Omsesidigt Portfolio

Follow Livforsakringsbolaget Skandia, Omsesidigt and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Livforsakringsbolaget Skandia, Omsesidigt, based on Form 13F filings with the SEC.

News

Stay updated on Livforsakringsbolaget Skandia, Omsesidigt with notifications on news.